By Eric Kroh ( June 16, 2017, 11:19 AM EDT) -- It has been four years since the U.S. Supreme Court ruled that brand-name drugmakers' payments to generics companies in patent settlements can raise antitrust concerns, but despite calls for clarity on such pay-for-delay deals, it is unclear if the justices will ever revisit the decision....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.